OCUL – ocular therapeutix, inc. (US:NASDAQ)
Stock Stats
News
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD [Seeking Alpha]
Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: VANGUARD GROUP INC
Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: BlackRock, Inc.
Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: VANGUARD GROUP INC
Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: BlackRock, Inc.
Form 144 OCULAR THERAPEUTIX, INC Filed by: Strassburger Philip C.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.